Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korea Q1 Roundup: Overseas Sales, COVID Prove Positive In Mixed Results

SK Bioscience Files For Vaccine

Executive Summary

Among recent highlights, SK Bioscience files for approval of recombinant protein COVID-19 vaccine GBP510, Hanmi Pharmaceutical’s Chinese subsidiary continues to report strong earnings, led by cold drug sales, while Yuhan’s novel peptide drug candidate for degenerative disc disease is set to move into a Phase III trial in the US.

You may also be interested in...



Spine Takes Yuhan’s Peptide Into US Phase III For High-Need DDD

Major Korean firm Yuhan is seeing progress across multiple novel drug candidates licensed out to global partners, with two now entering pivotal trials. An innovative therapy for degenerative disc disease licensed to Spine BioPharma has received an FDA nod for a Phase III program and may change the standard of care for chronic low back pain patients.

Next Big Step: SK Bioscience Gears Up For Endemic COVID, Next Pandemic

With its COVID-19 vaccine development project nearing the finish line, SK Bioscience unveils an ambitious growth strategy which includes mergers and acquisitions and diversification into the cell and gene therapy sector.

Looking Beyond CNS, SK Biopharm Begins First US Oncology Trial

The CNS-focused SK Group affiliate has set out ambitious growth plans for this year and is moving forward with a diversification into oncology and other areas, beginning its first US cancer trials in brain tumors and cancers with brain metastasis.

Topics

Related Companies

UsernamePublicRestriction

Register

SC146351

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel